0.000USD0.000Pre-market 07/24, 09:30 (ET)
125.07MMarket Cap
LossP/E TTM
Key Figures
1.790Open
1.825High
549.26KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.76%Turnover Ratio
1.800Prev. Close
1.730Low
685.16KTurnover
LossP/E Static
2.89P/B
0.00%Div Yield TTM
-63.16%ROA
2.94952wk High
0.64Volume Ratio
-46.06MNet Profit
72.29MShares
-0.5404EPS TTM
2.44Beta
-79.94%ROE
0.74152wk Low
5.28%Amplitude
-24677.94%Gross Margin
125.07MMarket Cap
-1.12Reward/Risk
6.02%Risk Rate
Currency: USD Updated: 2026-07-23 Key Insights
InflaRx NV's fundamentals are relatively stable, and its growth potential is good.Its valuation is considered fairly valued, ranking 145 out of 386 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.62.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
InflaRx NV Highlights
StrengthsRisks
InflaRx NV News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Ionis Pharmaceuticals Inc
IONS
26
Indicators
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
InflaRx NV Info
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
Ticker SymbolIFRX
CompanyInflaRx NV
CEORiedemann (Niels C)
Websitehttps://www.inflarx.de/
Shareholders
FAQs
What is the current price of InflaRx NV (IFRX)?
The current price of InflaRx NV (IFRX) is 1.73.
What is the symbol of InflaRx NV?
The ticker symbol of InflaRx NV is IFRX.
What is the 52-week high of InflaRx NV?
The 52-week high of InflaRx NV is 2.95.
What is the 52-week low of InflaRx NV?
The 52-week low of InflaRx NV is 0.74.
What is the market capitalization of InflaRx NV?
The market capitalization of InflaRx NV is 125.07M.
Is InflaRx NV (IFRX) currently rated as Buy, Hold, or Sell?
According to analysts, InflaRx NV (IFRX) has an overall rating of Buy, with a price target of 7.62.
What is the Earnings Per Share (EPS TTM) of InflaRx NV (IFRX)?
The Earnings Per Share (EPS TTM) of InflaRx NV (IFRX) is -0.80.
